The CAO of Stemline Therapeutics Inc (NASDAQ: STML) is Selling Shares

By Carrie Williams

Yesterday, the CAO of Stemline Therapeutics Inc (NASDAQ: STML), David Gionco, sold shares of STML for $156.6K.

Following David Gionco’s last STML Sell transaction on January 19, 2018, the stock climbed by 3.6%. In addition to David Gionco, 4 other STML executives reported Sell trades in the last month.

The company has a one-year high of $18 and a one-year low of $7.05. Currently, Stemline Therapeutics Inc has an average volume of 201.4K.

The insider sentiment on Stemline Therapeutics Inc has been negative according to 18 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. It develops a discovery platform called StemScreen, which identifies novel compounds that target and kill cancer stem cells.